Accelerating oncology drug discovery with HUB Organoids
Oncology drug development is especially risky with only 5% of new compounds reaching market approval. The lack of patient-relevant, early-stage preclinical models...
February 17, 2022
Oncology drug development is especially risky with only 5% of new compounds reaching market approval. The lack of patient-relevant, early-stage preclinical models...
